Physician profile
Patrick P Dugan
NPI 1932141991
$2,452.32
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $354 · 2021: $128 · 2022: $43.09 · 2023: $274 · 2024: $435 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $848.35 | 2019-2024 | Xtandi |
| Pfizer INC. | $259.66 | 2019-2025 | |
| Abbvie INC. | $134.11 | 2019-2024 | Botox |
| Dornier Medtech America, INC | $130.53 | 2024 | Dornier Medtech |
| Boston Scientific Corporation | $129.66 | 2019-2024 | Rezum Generator |
| Tolmar Pharmaceuticals, INC. | $99.43 | 2019 | |
| Ferring Pharmaceuticals INC. | $86.91 | 2019-2025 | Adstiladrin, Euflexxa |
| Endo Pharmaceuticals INC. | $85.09 | 2019 | |
| Sumitomo Pharma America, INC. | $83.88 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar, INC. | $72.83 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $68.39 | 2020-2024 | Keytruda, Welireg, Lynparza |
| Neotract INC. | $63.97 | 2019-2020 | |
| Axonics, INC. | $62.67 | 2023-2024 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $58.19 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $44.77 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $42.24 | 2024 | Aquabeam System |
| Myriad Genetic Laboratories, INC. | $36.37 | 2023 | Prolaris |
| Travere Therapeutics, INC. | $27.55 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $25.38 | 2024 | |
| Myovant Sciences INC. | $24.76 | 2021 | |
| Depuy Synthes Sales INC. | $22.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.89 | 2025 | |
| Coloplast Corp | $14.52 | 2025 | |
| Teleflex LLC | $13.81 | 2024 | Urolift |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$98.61 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dugan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.